Speaker(s): 

Jim Stevenson, PharmD, MS, BCPP, Staff Member, The Johns Hopkins University School of Medicine - has nothing to disclose. 

Moderator(s): 

Ryley Uber, PharmD, Staff Member, Geisinger - has nothing to disclose.   

Learning Objectives: 

At the conclusion of this session, the participant should be able to: 

• describe how PGx variation affects the pharmacokinetics and pharmacodynamics of antidepressants.
• review key clinical trials evaluating PGx in depression.
• identify specific challenges to PGx implementation in mental health.

Disclosure of Relevant Financial Relationships with/without Commercial Interests:

The Planning Committee consisting of Daniel Longyhore, PharmD, Ed.D., BCACP; Eric Wright, PharmD, MPH; Melissa Kern, MPH; Lisabeth Karetsky, CPhT and Nichole Varela Gonzalez have no identified disclosures. 

CE Committee Member/Content Reviewers have nothing to disclose.

Jeffrey Summers, DO and Karen Tillotson, DHSc, PA-C have nothing to disclose.

Any/All relevant financial relationships have been mitigated. 

Content Disclosure: 

This presentation/content is HIPPA compliant.